Decheng Pharmaceutical ADRX-0405 has been approved for clinical treatment of advanced solid tumors.

On June 9th, DeFeng Pharmaceutical announced that the China National Medical Products Administration has officially approved its clinical trial application for the investigational product ADRX-0405. The study aims to evaluate the efficacy and safety of ADRX-0405 in treating late-stage solid tumors. The company expects to complete the phase 1a study by the fourth quarter of 2026.